Amedica Corporation Reports Fourth Quarter and Full Year 2015 Financial Results

2015 Revenue of $19.5 Million at High End of Guidance

Operational Cash Burn Decreases by 38%

SALT LAKE CITY, March 17, 2016 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, today announced financial results for the fourth quarter and full-year ended December 31, 2015.

“During the last half of this year, and especially the fourth quarter, we were very active in the scientific development of silicon nitride and solidifying our foundation to support sustainable growth,” said Dr. Sonny Bal, chairman and CEO of Amedica Corporation. “In addition to strengthening our balance sheet and reducing cash burn, we’ve also placed a strong emphasis on increasing sales of our core product through a growing base of independent distributors, as well as the variety of discussions and transactions we’ve achieved in our business development efforts to-date. The increased interest and adoption of silicon nitride, coupled with our improved financial position, provide us with the competitive advantage necessary to build awareness and drive excitement for our unique biomaterial.”

Total product revenue was $19.5 million in 2015 as compared to $22.8 million in 2014, a decrease of $3.3 million or 15%. This decline was primarily due to lower metals sales as a result of a decline in the level of activity for a few key surgeons and the consequences from restructuring efforts taken earlier in the year. Silicon nitride sales decreased by $0.7 million, or 6%, as compared to the same period in 2014. The decline was partially offset by the addition of new surgeons, re-engaging lost surgeons, and increased international and private label sales.

Cost of revenue decreased $1.7 million, or 21%, as compared to the same period in 2014. The decrease in cost of revenue was primarily a result of reduced sales and a decrease in excess and obsolete inventory in 2015, as compared to the same period in 2014. Excluding the impact of excess or obsolete inventory for both years, 2015 gross margins ended at 75% of total sales, as compared to 77% during the prior year period. Although product costs have been reduced through production efficiencies and lower overhead costs, the decline in gross margins was due to private label and increased international sales during 2015, which have lower gross margins due to lower selling prices, but have higher operating contribution margins since no commissions are paid on those sales and it requires less operating expenses to support these sales.

Operating expenses decreased $13.8 million, or 35%, as compared to the same period in 2014. This decline in operating expenses was primarily due to the actions taken by the Company to simplify the organization and align financial objectives earlier in the year, as well as lower commission costs and a $9.0 million reduction in stock-based compensation expense during 2015.

Net loss for the full year 2015 was $23.9 million, compared to $32.6 million in the prior-year period, primarily as a result of a decrease in non-cash stock compensation expense of approximately $9.0 million, lower operating expenses and lower offering costs incurred during the year.  This was partially offset by a loss recognized on the issuance of warrants and increased interest expense.  The majority of the derivative liabilities have been extinguished as a result of the completion of the most recent equity financing.

Adjusted EBITDA, which is defined as earnings before deductions for interest, taxes, depreciation, amortization, non-cash stock compensation expense, change in fair value of derivative liabilities, offering costs, loss on extinguishment of derivative liabilities and loss on extinguishment of debt for the full-year 2015 was $9.0 million, compared to a loss of $11.9 million for the full-year 2014.

Cash and cash equivalents totaled $11.5 million as of December 31, 2015. The decline in total cash burn year-over-year was driven by a decrease in operational cash burn of $5.5 million in 2015, as compared to the prior year period. Total principal debt obligations were $17.8 million as of December 31, 2015, a decrease of $6.7 million from December 31, 2014.

Conference Call
The Company will hold an investor conference call to discuss the financial results on Thursday March 17, 2016 at 5:00 PM Eastern Time. The Company invites all interested parties to join the call by dialing Toll Free (855) 455-6055, any time after 4:50 p.m. Eastern Time on March 17th. The Conference ID number is 63087706. International callers should dial (484) 756-4308. For those who are not available to listen to the live webcast, a telephone replay will be available for one week following the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants. When prompted, please enter the Conference ID number 63087706. The call will also be archived on the investor relations section of the Amedica website under Events & Presentations.

Non-GAAP Financial Measures
This press release includes the following "non-GAAP financial measures" as defined by the Securities and Exchange Commission (SEC): Adjusted EBITDA and Gross Margin Before deducting the Provision for Excess and Obsolete Inventory. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation of, or as a substitute for, the financial information prepared and presented in accordance with generally accepted accounting principles (GAAP). For a reconciliation of these non-GAAP financial measures to the nearest comparable GAAP measure, see "Reconciliation of Non-GAAP Financial Measures" included in this press release. 

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995.  Forward-looking statements contained in this press release include the intent, belief or current expectations of Amedica and members of its management team with respect to Amedica's future business operations as well as the assumptions upon which such statements are based. Forward-looking statements include specifically, but are not limited to, Amedica's market opportunities, growth, future products, market acceptance of its products, sales and financial results and such statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of Amedica's products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2015, and in Amedica's other filings with the SEC.  Amedica disclaims any obligation to update any forward-looking statements.

Amedica Corporation
Consolidated Balance Sheets - Unaudited
(in thousands, except share and per share data)
  Year Ended December 31, 
    2015       2014  
Current assets:      
Cash and cash equivalents $ 11,485     $ 18,247  
Trade accounts receivable, net of allowance of $49 and $54,
  2,660       2,513  
Prepaid expenses and other current assets   821       1,247  
Inventories, net   9,131       11,675  
Total current assets   24,097       33,682  
Property and equipment, net   2,472       3,515  
Intangible assets, net   3,687       4,188  
Goodwill   6,163       6,163  
Other long-term assets   35       35  
Total assets $ 36,454     $ 47,583  
Liabilities and stockholders’ equity      
Current liabilities:      
Accounts payable $ 643     $ 778  
Accrued liabilities   3,421       3,146  
Current portion of long-term debt   16,957       19,070  
Total current liabilities   21,021       22,994  
Deferred rent   432       517  
Long-term debt   -       3,061  
Other long-term liabilities   171       134  
Derivative liabilities   598       13,970  
Commitments and contingencies      
Convertible preferred stock, $0.01 par value, 130,000,000 shares
authorized; 0 shares issued and outstanding at December 31, 2015
and 2014
  -       -  
Stockholders’ equity:      
Common stock, $0.01 par value; 250,000,000 shares authorized;
10,886,046 and 1,756,911 shares issued and outstanding at December
31, 2015 and 2014, respectively
  109       16  
Additional paid-in capital   210,660       179,396  
Accumulated deficit   (196,537 )     (172,505 )
Total stockholders’ equity   14,232       6,907  
Total liabilities, convertible preferred stock and stockholders’ equity $ 36,454     $ 47,583  

Amedica Corporation      
Consolidated Statements of Operations and Comprehensive Loss - Unaudited      
(in thousands, except share and per share data)      
  Year Ended December 31,
    2015       2014  
Product revenue $ 19,453     $ 22,765  
Costs of revenue   6,250       7,910  
Gross profit   13,203       14,855  
Operating expenses:      
Research and development   6,387       6,742  
General and administrative   6,436       13,588  
Sales and marketing   12,421       18,692  
Total operating expenses   25,244       39,022  
Loss from operations   (12,041 )     (24,167 )
Other income (expense):      
Interest income   -       12  
Interest expense   (4,339 )     (3,650 )
Gain (loss) on extinguishment of debt   2,171       (2,194 )
Change in fair value of derivative liabilities   (7,605 )     (251 )
Loss on extinguishment of derivative liabilities   (1,263 )     -  
Offering costs   (821 )     (2,026 )
Other expense   (14 )     (306 )
Total other income (expense)   (11,871 )     (8,415 )
Net loss before income taxes   (23,912 )     (32,582 )
Provision for income taxes   -       -  
Net comprehensive loss $ (23,912 )   $ (32,582 )
Other comprehensive loss, net of tax:      
Unrealized loss on marketable securities   -       -  
Total comprehensive loss $ (23,912 )   $ (32,582 )
Net loss per share attributable to common stockholders:      
Basic and diluted $ (5.50 )   $ (39.93 )
Weighted average common shares outstanding:      
Basic and diluted   4,344,253       815,997  

Amedica Corporation        
Condensed Consolidated Statements of Cash Flows - Unaudited        
(in thousands)        
    Year Ended December,
      2015       2014  
Cash flow from operating activities        
Net loss   $ (23,912 )   $ (32,582 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense     1,652       1,839  
Amortization of intangible assets     501       501  
Amortization of lease incentive for tenant improvements     20       20  
Non cash interest expense     2,194       1,849  
(Gain) loss on extinguishment of debt     (2,171 )     2,194  
Stock based compensation     911       10,217  
Change in fair value of derivative liabilities     7,605       251  
Loss on extinguishment of derivative liabilities     1,263       -  
(Gain) loss on disposal of equipment     (21 )     305  
Provision for inventory reserve     1,333       2,630  
Bad debt expense     (27 )     65  
Offering costs     821       2,026  
Changes in operating assets and liabilities:        
Trade accounts receivable     (120 )     239  
Prepaid expenses and other current assets     (74 )     2,775  
Inventories     1,357       (3,438 )
Accounts payable and accrued liabilities     (395 )     (3,413 )
Net cash used in operating activities     (9,063 )     (14,522 )
Cash flows from investing activities        
Purchase of property and equipment     (695 )     (2,172 )
Proceeds from sale of property and equipment     37       43  
Decrease in restricted cash     -       392  
Net cash used in investing activities     (658 )     (1,737 )
Cash flows from financing activities        
Proceeds from issuance of common stock, net of issuance costs     4,337       15,369  
Proceeds from issuance of units, net of issuance costs     -       11,320  
Proceeds from issuance of stock in connection with exercise of warrants, net of issuance costs     5,863       -  
Payments on long-term debt     (2,949 )     (19,000 )
Debt extinguishment payments     (4,112 )     (810 )
Proceeds from issuance of long-term debt       -       26,800  
Payment of deferred financing costs     (60 )     (1,452 )
Purchase of treasury stock     (120 )     -  
Net cash provided by financing activities     2,959       32,227  
Net increase (decrease) in cash and cash equivalents     (6,762 )     15,968  
Cash and cash equivalents at beginning of period     18,247       2,279  
Cash and cash equivalents at end of period   $ 11,485     $ 18,247  

Reconciliation of Non-GAAP Financial Measures:

To supplement our consolidated statements of operations and comprehensive net loss which are presented in accordance with GAAP, we use certain non-GAAP measures of components of financial performance. Although not measures of financial performance under GAAP, “Adjusted EBITDA” and “Gross Margin Before deducting the Provision for Excess and Obsolete Inventory” are provided for the use of investors in understanding our operating results and are not prepared in accordance with, nor do they serve as alternatives to GAAP measures, and may be materially different from similar measures used by other companies. We define "Adjusted EBITDA" as our earnings before deductions for interest, taxes, depreciation, amortization, stock-based compensation, change in fair value of derivative liabilities, offering costs, loss on extinguishment of derivative liabilities and loss on extinguishment of debt.  We define “Gross Margin Before deducting the Provision for Excess and Obsolete Inventory” as our gross margin before deducting the provision for excess and obsolete inventory. While not a substitute for information prepared in accordance with GAAP, management believes that this information is helpful for investors to more easily understand our operating financial performance. Management also believes these measures may better enable an investor to form views of our potential financial performance in the future. These measures have limitations as analytical tools, and investors should not consider these measures in isolation or as a substitute for analysis of our results prepared in accordance with GAAP. 

Below is a reconciliation of Adjusted EBITDA to Net Loss for each of the periods presented (in thousands - unaudited):

  Year Ended December 31, 
    2015       2014  
Net Loss $ (23,912 )   $ (32,582 )
Interest expense, net   4,339       3,638  
Income tax expense   -       -  
Depreciation   1,652       1,839  
Amortization   501       501  
Stock-based compensation   911       10,217  
Change in fair value of derivative liabilities   7,605       251  
Loss on extinguishment of derivative liabilities   1,263       -  
Offering costs   821       2,026  
Loss on extinguishment of debt   (2,171 )     2,194  
Adjusted EBITDA $ (8,991 )   $ (11,916 )

Below is a reconciliation of Gross Profit and Margin to Gross Profit and Margin Before deducting the Provision for Excess and Obsolete Inventory for each of the periods presented (in thousands - unaudited):

  Year Ended December 31, 2015   Year Ended December 31, 2014
  Gross Profit   Gross Margin   Gross Profit   Gross Margin
Gross profit and margin $   13,203       68 %   $   14,855       65 %
Provision for excess and obsolete inventory     1,334       7 %       2,630       12 %
Gross profit and margin, excluding provision for excess and obsolete inventory  $   14,537       75 %   $   17,485       77 %

About Amedica Corporation

Amedica is focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company manufactures its products in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, the world's largest ceramic manufacturer. Amedica's spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM partnerships.

For more information on Amedica or its silicon nitride material platform, please visit

Mike Houston
VP, Commercialization

Robert Haag
Managing Director
IRTH Communications

Primary Logo

Source: Amedica Corporation